Advances in Co-Processed Excipients: Multifunctional Platforms for Diverse Pharmaceutical Formulations

As it adds so many advantages to the finished formulations, excipient utilised in pharmaceutical dosage forms is a special and important ingredient that is just as important as the API. Improving API absorption and bioavailability, boosting organoleptic characteristics and filling the entire tablet are among the benefits. Nevertheless, choosing the right excipients remain taxing due to matters including the various attributes of excipients, incompatibility between API and excipient, moisture absorption capacity, surface acidity, crystal nature and production of hazardous excipients that are inferior, among other issues. The substantial toxicity of the excipient may have a significant effect on the pharmacokinetic and pharmacodynamic properties of the API and its dosage form. It can be the result of utilising several excipients that perform inconsistently. The pharmaceutical sector can address its excipient-related problems by embracing and enforcing cGMP, but this won’t stop the production process from being affected by the long, costly and laborious regulatory procedure. Co-processed excipients have multiple uses, thus when creating dosage forms, they might give formulation scientists something unique. An alternative and potential method for choosing and utilising an ideal combination of currently available excipients over the conventional excipients in the preparation of dosage forms is made possible by the need for co-processed excipients, the need for excipients to be co-processed, development techniques, risk and valuation studies, use and compliance with standards.